Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason K Russell

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Opinion in Neurology|February 19, 2026
Decoding Alzheimer's disease through down syndrome: insights from a genetically defined populationJason K Russell, Zinayida Schlachetzki, Michael S Rafii
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 1, 2019
The Role of Estrogen in Brain and Cognitive AgingJason K Russell, Carrie K Jones, Paul A Newhouse
JAMA Neurology|January 12, 2026
Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down SyndromeJason K Russell, Zinayida Schlachetzki, Beau M Ances, et al.
Current Topics in Behavioral Neurosciences|November 1, 2024
Cholinergic System Structure and Function Changes in Individuals with Down Syndrome During the Development of Alzheimer's DiseaseJason K Russell, Alexander C Conley, Jo Ellen Wilson, et al.
ACS Chemical Neuroscience|January 19, 2023
M<sub>1</sub>/M<sub>4</sub>-Preferring Muscarinic Cholinergic Receptor Agonist Xanomeline Reverses Wake and Arousal Deficits in Nonpathologically Aged MiceJason K Russell, Shalonda M Ingram, Laura B Teal, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 11, 2026
Relationship of cholinergic basal forebrain atrophy with the time course of Alzheimer's disease pathology and cognitive decline in adults with Down syndrome: a longitudinal cohort studyJason K Russell, Zinayida Schlachetzki, Alexander C Conley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 26, 2026
Facial feature removal in magnetic resonance imaging scans of adults with Down syndrome: A de-facing methodological studyJason K Russell, Michael S Rafii, Walter K Kremers, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 2, 2020
Modulation of arousal and sleep/wake architecture by M<sub>1</sub> PAM VU0453595 across young and aged rodents and nonhuman primatesRobert W Gould, Jason K Russell, Michael T Nedelcovych, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Opinion in Neurology|February 19, 2026
Decoding Alzheimer's disease through down syndrome: insights from a genetically defined populationJason K Russell, Zinayida Schlachetzki, Michael S Rafii
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 1, 2019
The Role of Estrogen in Brain and Cognitive AgingJason K Russell, Carrie K Jones, Paul A Newhouse
JAMA Neurology|January 12, 2026
Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down SyndromeJason K Russell, Zinayida Schlachetzki, Beau M Ances, et al.
Current Topics in Behavioral Neurosciences|November 1, 2024
Cholinergic System Structure and Function Changes in Individuals with Down Syndrome During the Development of Alzheimer's DiseaseJason K Russell, Alexander C Conley, Jo Ellen Wilson, et al.
ACS Chemical Neuroscience|January 19, 2023
M<sub>1</sub>/M<sub>4</sub>-Preferring Muscarinic Cholinergic Receptor Agonist Xanomeline Reverses Wake and Arousal Deficits in Nonpathologically Aged MiceJason K Russell, Shalonda M Ingram, Laura B Teal, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 11, 2026
Relationship of cholinergic basal forebrain atrophy with the time course of Alzheimer's disease pathology and cognitive decline in adults with Down syndrome: a longitudinal cohort studyJason K Russell, Zinayida Schlachetzki, Alexander C Conley, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 26, 2026
Facial feature removal in magnetic resonance imaging scans of adults with Down syndrome: A de-facing methodological studyJason K Russell, Michael S Rafii, Walter K Kremers, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 2, 2020
Modulation of arousal and sleep/wake architecture by M<sub>1</sub> PAM VU0453595 across young and aged rodents and nonhuman primatesRobert W Gould, Jason K Russell, Michael T Nedelcovych, et al.
Research Square|April 16, 2025
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy ParticipantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Alzheimer'S Research & Therapy|July 2, 2025
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M<sub>1</sub> positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participantsAlexander C Conley, Alexandra P Key, Jennifer U Blackford, et al.
Pageof 2